Subscribe
sebra-shutterstock-com-court-gavel--1
9 January 2017Americas

Sanofi and Regeneron to appeal against Praluent injunction

Sanofi and Regeneron Pharmaceuticals have revealed plans to appeal against an injunction granted to Amgen, which prevents the companies from selling cholesterol-lowering medicine Praluent (alirocumab).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sanofi and Regeneron’s appeal to suspend Amgen injunction denied
12 January 2017   A US District Court has denied Sanofi and Regeneron’s motion to suspend an injunction which was obtained by Amgen earlier this month.
Americas
Amgen wins injunction in Sanofi Repatha suit
6 January 2017   Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.
Americas
Amgen secures patent win in Repatha case
4 January 2017   Amgen secured victory yesterday as a US federal judge refused to throw out a ruling upholding the validity of two patents owned by the company.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Sanofi and Regeneron’s appeal to suspend Amgen injunction denied
12 January 2017   A US District Court has denied Sanofi and Regeneron’s motion to suspend an injunction which was obtained by Amgen earlier this month.
Americas
Amgen wins injunction in Sanofi Repatha suit
6 January 2017   Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.
Americas
Amgen secures patent win in Repatha case
4 January 2017   Amgen secured victory yesterday as a US federal judge refused to throw out a ruling upholding the validity of two patents owned by the company.

More on this story

Americas
Sanofi and Regeneron’s appeal to suspend Amgen injunction denied
12 January 2017   A US District Court has denied Sanofi and Regeneron’s motion to suspend an injunction which was obtained by Amgen earlier this month.
Americas
Amgen wins injunction in Sanofi Repatha suit
6 January 2017   Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.
Americas
Amgen secures patent win in Repatha case
4 January 2017   Amgen secured victory yesterday as a US federal judge refused to throw out a ruling upholding the validity of two patents owned by the company.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB